We protect your health through science
Investigación
Leishmaniasis and Chagas Disease
Publicaciones destacadas
Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study
Jiménez-Jorge S, Pozo F, de Mateo S, Delgado-Sanz C, Casas I, García-Cenoz M, Castilla J, Sancho R, Etxebarriarteun-Aranzabal L, Quinones C, Martínez E, Vega T, Garcia A, Giménez J, Vanrell JM, Castrillejo D, Larrauri A, on behalf of the Spanish Influenza Sentinel Surveillance System (SISS). Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study. Euro Surveill. 2014 Mar 6;19(9). Indice Impacto: 5,722. Revista en Q1.
PUBMED DOIY155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors
Perez-Sautu U, Pozo F, Cuesta I, Monzon S, Calderon A, Gonzalez M, Molinero M, Lopez-Miragaya I, Rey S, Cañizares A, Rodriguez G, Gonzalez-Velasco C, Lackenby A, Casas I. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors. Euro Surveill. 2014 Jul 10;19(27):14-20. Indice Impacto: 5,722. Revista en Q1
PUBMED DOICharacterization In Vitro and In Vivo of a Pandemic H1N1 Influenza Virus from a Fatal Case.
Rodriguez A, Falcon A, Cuevas MT, Pozo F, Guerra S, García-Barreno B, Martinez-Orellana P, Pérez-Breña P, Montoya M, Melero JA, Pizarro M, Ortin J, Casas I, Nieto A. Characterization In Vitro and In Vivo of a Pandemic H1N1 Influenza Virus from a Fatal Case. PLoS One. 2013;8(1):e53515. doi: 10.1371/journal.pone.0053515. Epub 2013 Jan 10. Indice Impacto: 3,534. Revista en Q1
PUBMED DOIMycobacterium tuberculosis genotypes and predominant clones among the multidrug-resistant isolates in Spain 1998-2006
3. Samper S, Gavin P, Millan-Lou MI, Iglesias M.J. Jimenez MS. Spanish Working Group on MDR-TB, Covin D, Rastogi N. Mycobacterium tuberculosis genotypes and predominant clones among the multidrug-resistant isolates in Spain 1998-2006. Infec Genet Evol. 2017. Aug 5;55:117.
PUBMED DOIAntitubercular drugs for an old target: GSK693 as a promising inhA direct inhibitor.
5. Martinez-Hoyos M, Perez-Herran E, Gulten G, Encinas L, Alvarez-Gomez D, Alvarez E, Ferrer Bazaga S, Garcia-Perez A, Ortega F, Angulo-Bartures I, Rullas-Trincado J, Blanco Ruano D, Torres P, Castañeda P, Huss S, Fernandez R, Gonzalez del Valle S, Ballel L, Barros D, Modha S, Dhar N, Signorino-Gelo F, McKinney JD, Garcia-Bustos JF, Lavandera JL, Sacchettini JC, Jimenez MS, Martin-Casabona N, Castro-PIchel J, Mendoza-Losana A. Antitubercular drugs for an old target: GSK693 as a promising inhA direct inhibitor. EBioMedicine. 2016; 8:291-301
PUBMED DOIContent with Investigacion .
-
Isabel de Fuentes Corripio
Jefa de Unidad, Investigador Titular OPIS
-
David Carmena Jiménez
Investigador Doctor distinguido
-
Aly Salimo Omar Muadica
Becario pre-doctoral
-
Marta Hernández de Mingo
Colaborador I+D+I
-
Begoña Bailo Cardoso
Técnico de Laboratorio
-
María Aguilera
Técnico de laboratorio
-
David González Barrio
Investigador contratado
List of staff
Información adicional
The Leishmaniasis and Chagas Disease Unit supports the National Health System through a multidisciplinary approach that includes the development and validation of diagnostic tests, the molecular characterization of parasites, molecular epidemiology, field studies, as well as experimental research into new therapeutic and prophylactic approaches for their control.
The laboratory has extensive experience in the characterization of the cellular and humoral immune response of leishmaniasis and post-treatment monitoring, as well as in asymptomatic individuals and in experimental animal models. The laboratory also contributes to immunological studies of the pathogenesis of leishmaniasis under immunosuppressive conditions (HIV/Leishmania co-infection, malnutrition, immunosuppressive treatment...). The laboratory has been a WHO Collaborating Center for Leishmaniasis since 1997, providing technical support to the various research and training activities of the WHO and participating in the evaluation of outbreaks of human leishmaniasis in endemic countries.
The laboratory also participates in the evaluation of prognostic markers for the evolution of T. cruzi infection and vertical (transplacental) transmission, an important public health problem in our country. It also carries out studies on the pharmacokinetics of drugs against Chagas disease.